You have read all your free articles, to continue reading subscribe to read the rest of this content.
AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters Already a subscriber Login You have read all…
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema. As part of the offering Herantis issued a total of 618,018 new shares at a price of €6.72 EUR / SEK 71 per share bringing the total number…
AstraZeneca has entered into a new global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen, formerly known as IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense investigational medicine currently in Phase III clinical trials for amyloid transthyretinAlready a subscriber Login You have read all your free articles, to continue reading subscribe…
AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. "This agreement supports the managemeAlready a subscriber Login You have read all…
